| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1538-7836.2004.00789.X |
| P8608 | Fatcat ID | release_upo7i7fpr5hcfgnwilxbzwukr4 |
| P698 | PubMed publication ID | 15304034 |
| P5875 | ResearchGate publication ID | 8407190 |
| P50 | author | Al M Best | Q79985905 |
| P2093 | author name string | Martin EJ | |
| Gehr TW | |||
| Brophy DF | |||
| Carr ME | |||
| P2860 | cites work | The dynamics of thrombin formation | Q28610129 |
| Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes | Q28645789 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency | Q33977626 | ||
| Platelets, leukocytes, and coagulation. | Q34403977 | ||
| Platelets and thrombin generation | Q34858543 | ||
| Development of platelet contractile force as a research and clinical measure of platelet function | Q35094125 | ||
| Enoxaparin in unstable angina patients with renal failure | Q43749388 | ||
| Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment | Q43942837 | ||
| Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin | Q44484806 | ||
| Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies | Q44507061 | ||
| Delayed elimination of enoxaparine in patients with chronic renal insufficiency | Q44546046 | ||
| Effect of Non-Heparin Thrombin Antagonists on Thrombin Generation, Platelet Function, and Clot Structure in Whole Blood | Q44600076 | ||
| Delayed, reduced or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation | Q44887251 | ||
| Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies | Q44894913 | ||
| Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT). | Q44895519 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1299-1304 | |
| P577 | publication date | 2004-08-01 | |
| P1433 | published in | Journal of Thrombosis and Haemostasis | Q6296004 |
| P1476 | title | Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction | |
| P478 | volume | 2 |
| Q30380515 | A portable blood plasma clot micro-elastometry device based on resonant acoustic spectroscopy. |
| Q26995027 | A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency |
| Q38442992 | Anticoagulation in Chronic Hemodialysis: Progress Toward an Optimal Approach |
| Q42837054 | Bridge-therapy with enoxaparin in the preoperative period of endarterectomy |
| Q35669517 | Mechanobiology of platelets: techniques to study the role of fluid flow and platelet retraction forces at the micro- and nano-scale |
| Q43879938 | No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease. |
| Q44921971 | The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies. |
| Q44916643 | Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. |
| Q59636551 | Thromboelastometry versus free-oscillation rheometry and enoxaparin versus tinzaparin: an in-vitro study comparing two viscoelastic haemostatic tests' dose-responses to two low molecular weight heparins at the time of withdrawing epidural catheters f |
| Q36154876 | Venous thromboembolism prevention in acutely ill nonsurgical patients |
Search more.